73,416 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 73,416 shares of the company’s stock, valued at approximately $6,956,000. Jefferies Financial Group Inc. owned approximately 0.50% of Inhibrx Biosciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of INBX. Bank of America Corp DE bought a new stake in shares of Inhibrx Biosciences in the 2nd quarter worth approximately $79,698,000. BlackRock Inc. bought a new position in shares of Inhibrx Biosciences during the 2nd quarter valued at $78,261,000. Morgan Stanley grew its holdings in shares of Inhibrx Biosciences by 163.7% during the 4th quarter. Morgan Stanley now owns 1,167,728 shares of the company’s stock valued at $92,251,000 after purchasing an additional 724,872 shares during the last quarter. Capital Research Global Investors purchased a new position in Inhibrx Biosciences in the 4th quarter worth $33,304,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Inhibrx Biosciences in the 4th quarter worth $20,856,000. 82.46% of the stock is currently owned by institutional investors.

Inhibrx Biosciences News Roundup

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright’s bullish rating and price target indicate confidence in Inhibrx’s longer-term prospects, representing the primary positive catalyst in the reports.
• Neutral Sentiment: The analyst projects continued quarterly losses but expects losses to narrow from approximately $8.93 per share in fiscal 2026 to $8.47 per share in fiscal 2027. Estimates include losses of $2.14 per share in Q3 2026 and $2.30 per share in Q4 2026, followed by quarterly losses ranging from $2.02 to $2.22 in 2027.
• Negative Sentiment: Inhibrx remains unprofitable, and the projected losses could limit near-term enthusiasm despite the favorable analyst rating. The company also recently reported an earnings-per-share miss, underscoring ongoing execution and development risks.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on INBX. Wall Street Zen lowered shares of Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. HC Wainwright initiated coverage on Inhibrx Biosciences in a report on Monday. They issued a “buy” rating and a $245.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. Finally, Citigroup restated a “market perform” rating on shares of Inhibrx Biosciences in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $197.50.

Inhibrx Biosciences Trading Down 1.1%

Shares of INBX opened at $123.93 on Friday. The stock has a market capitalization of $1.82 billion, a P/E ratio of -13.96 and a beta of 3.51. Inhibrx Biosciences, Inc. has a twelve month low of $26.19 and a twelve month high of $155.29. The company has a quick ratio of 5.07, a current ratio of 5.07 and a debt-to-equity ratio of 12.58. The firm has a fifty day simple moving average of $93.69 and a two-hundred day simple moving average of $90.40.

Inhibrx Biosciences (NASDAQ:INBX) last released its quarterly earnings data on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). On average, research analysts anticipate that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current year.

About Inhibrx Biosciences

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.